| distal jejunal-release dextrose (APHD-012) / Aphaia Pharma |
2020-005989-34: Clinical trial involving the hospitals from different countries where patients are allocated to two groups of treatment: investigational product or the medicine which looks like the investigational product but doesn’t contain the active substance. The allocation is done by chance and neither Investigator, nor patient will know the group. The purpose of this trial is to evaluate the efficacy and safety of the investigational product. Participants should be diagnosed with obesity. |
|
|
| Not yet recruiting | 2 | 150 | Europe | Aphaia Technology (AT), APHD-012, Coated granules in sachet | Aphaia Pharma AG, Aphaia Pharma AG | Obesity with/without associated endocrine and/or metabolic conditions and/or hypertension and/or NASH and/or NAFL with/without fibrosis, obesity, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2022-003205-29: A Phase II, randomized, placebo – controlled crossover study to evaluate efficacy and safety of dextrose beads formulation (APHD-012) released in small intestine in subjects with a Oral Glucose Tolerance Test (OGTT) out of normal ranges Randomizované, placebom kontrolované klinické skúšanie fázy II s prekrížením liečby na vyhodnotenie účinnosti a bezpečnosti dextrózových guličiek (APHD-012), ktoré sa uvoľňujú v tenkom čreve u osôb s orálnym glukózovým tolerančným testom (OGTT) mimo normálnych hodnôt |
|
|
| Not yet recruiting | 2 | 30 | Europe | APHD-012, APHD-012, Coated granules in sachet | Aphaia Pharma US LLC, Aphaia Pharma US LLC | Subjects with a pathological Oral Glucose Tolerance Test (OGTT) pacienti s patologickými hodnotami orálneho glukózového tolerančného testu (OGTT), Patients with Oral Glucose Tolerance Test (OGTT) out of normal ranges Pacienti u ktorých sú výsledky orálneho glukózového tolerančného testu (OGTT) mimo normálnych hodnôt, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT05803772: A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation (APHD-012) in Subjects With a Pathological Oral Glucose Tolerance Test (OGTT) |
|
|
| Recruiting | 2 | 30 | Europe | APHD-012, Distal jejunal-release dextrose beads, APH-012P, Placebo | Aphaia Pharma US LLC | PreDiabetes, Glucose Tolerance Impaired | 10/23 | 10/23 | | |
NCT05385978: A Study of Distal Jejunal-release Dextrose in Obese Participants |
|
|
| Recruiting | 2 | 150 | Europe, US | APHD-012, Distal jejunal-release dextrose beads, APHD-012P, Placebo | Aphaia Pharma US LLC | Obese | 03/24 | 03/24 | | |
